EGFR and non-small cell lung carcinoma: HGF, MET-amplification and EGFR-T790M upregulate PD-L1 expression in NSCLC through different mechanisms, attenuating lymphocyte activation and cytotoxicity in vitro and in vivo, and promoting immune escape of tumor cells (Peng et al., 2019).